Bloom Burton

Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to reduce metabolic risk and prevent chronic diseases. Founded in 2008, Newtopia utilizes a proprietary virtual platform that combines personal genetics with social and psychological insights to create personalized health plans. By addressing unhealthy lifestyles, the company aims to mitigate the economic and social consequences associated with obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to make healthier lifestyle choices, demonstrating a proven model with an 80% success rate among early clients. The company targets partnerships with insurers, self-insured employers, and brands, offering sustainable health outcomes and a significant return on investment, making it a promising B2B collaborator in the health sector.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company addresses unmet medical needs by advancing a diverse portfolio of anti-infective therapies. This includes Favipiravir, aimed at treating pandemic influenza and COVID-19, as well as ATI-2307, an antifungal candidate in clinical trials for cryptococcal meningitis and invasive candidiasis. Additionally, Appili is developing ATI-1501, a taste-masked oral formulation of metronidazole, and ATI-1503, targeting gram-negative bacteria. The company also works on ATI-1701, a live-attenuated vaccine for Francisella tularensis, illustrating its commitment to improving patient outcomes in the face of serious infections.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company addresses unmet medical needs by advancing a diverse portfolio of anti-infective therapies. This includes Favipiravir, aimed at treating pandemic influenza and COVID-19, as well as ATI-2307, an antifungal candidate in clinical trials for cryptococcal meningitis and invasive candidiasis. Additionally, Appili is developing ATI-1501, a taste-masked oral formulation of metronidazole, and ATI-1503, targeting gram-negative bacteria. The company also works on ATI-1701, a live-attenuated vaccine for Francisella tularensis, illustrating its commitment to improving patient outcomes in the face of serious infections.

AceAge is a healthcare technology company focused on enhancing health outcomes for aging individuals through innovative products. The company's flagship product, Karie, is a home health appliance designed to help users manage their medication routines effectively. Karie organizes, schedules, and dispenses pills with one-button control, addressing the critical issue of medication nonadherence, which costs the U.S. healthcare system approximately $290 billion annually. By automating daily medication routines, Karie minimizes human error and supports greater patient autonomy, ultimately improving compliance with prescribed medical directions. The device utilizes common multi-dose pouch packaging that can be pre-set by pharmacists, ensuring that doses are delivered and monitored accurately. Through its user-friendly design, AceAge aims to enhance patient health while reducing the necessity for emergency care visits and assisted living admissions.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Antibe Therapeutics Inc. is a pharmaceutical development company focused on creating novel therapeutics to address pain, inflammation, and regenerative medicine. The company is dedicated to developing safer alternatives to traditional non-steroidal anti-inflammatory drugs (NSAIDs), which often lead to gastrointestinal complications. Its lead compound, ATB-346, is designed to treat conditions such as rheumatoid arthritis and ankylosing spondylitis, having successfully completed a Phase 2B gastrointestinal safety study. Antibe's pipeline also includes ATB-352, in preclinical development for treating gout and post-surgical pain, and ATB-340, targeting stroke and cancer. Additionally, Antibe provides various medical products, including bone graft substitutes and barrier membranes, for dental and orthopedic applications. Headquartered in Toronto, Canada, Antibe Therapeutics leverages its proprietary hydrogen sulfide platform to enhance the therapeutic potential of existing drugs while guided by a team of accomplished researchers and advisors.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company addresses unmet medical needs by advancing a diverse portfolio of anti-infective therapies. This includes Favipiravir, aimed at treating pandemic influenza and COVID-19, as well as ATI-2307, an antifungal candidate in clinical trials for cryptococcal meningitis and invasive candidiasis. Additionally, Appili is developing ATI-1501, a taste-masked oral formulation of metronidazole, and ATI-1503, targeting gram-negative bacteria. The company also works on ATI-1701, a live-attenuated vaccine for Francisella tularensis, illustrating its commitment to improving patient outcomes in the face of serious infections.

HLS Therapeutics Inc is a specialty pharmaceutical company that focuses on the acquisition and commercialization of branded pharmaceutical products primarily in North America. The company is committed to managing the life cycles of these products after their exclusivity, ensuring that essential treatments remain accessible to patients and caregivers. HLS Therapeutics offers a range of products, including Clozaril and Vascepa, and generates revenue mainly through product sales, supplemented by royalties. Operating in Canada, the United States, and other international markets, HLS Therapeutics plays a crucial role in maintaining the availability of trusted medications.

Hamilton Thorne, Inc. specializes in advanced laser systems and instruments for in-vitro cell applications, primarily serving the regenerative medicine and fertility clinic markets. Its ZILOS-tk and XYClone laser systems, designed to attach to standard inverted microscopes, function as robotic micro-surgeons, enhancing efficiency in stem cell, embryo, and living cell procedures. The company's CASA systems improve the quality and reliability of studies involving reproductive cells in both human and animal contexts, including infertility and reproductive toxicology. Hamilton Thorne's innovative laser technologies significantly reduce the time required to develop transgenic animal models and minimize cell damage during procedures, resulting in higher yields. The company caters to a diverse clientele, including pharmaceutical and biotechnology firms, fertility clinics, and prominent university research centers, with notable customers such as Harvard, MIT, and Pfizer.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to reduce metabolic risk and prevent chronic diseases. Founded in 2008, Newtopia utilizes a proprietary virtual platform that combines personal genetics with social and psychological insights to create personalized health plans. By addressing unhealthy lifestyles, the company aims to mitigate the economic and social consequences associated with obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to make healthier lifestyle choices, demonstrating a proven model with an 80% success rate among early clients. The company targets partnerships with insurers, self-insured employers, and brands, offering sustainable health outcomes and a significant return on investment, making it a promising B2B collaborator in the health sector.

Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and providing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used for the treatment of hypertension. Noden Pharma aims to enhance the lives of patients by offering effective medical solutions in international markets.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Hamilton Thorne, Inc. specializes in advanced laser systems and instruments for in-vitro cell applications, primarily serving the regenerative medicine and fertility clinic markets. Its ZILOS-tk and XYClone laser systems, designed to attach to standard inverted microscopes, function as robotic micro-surgeons, enhancing efficiency in stem cell, embryo, and living cell procedures. The company's CASA systems improve the quality and reliability of studies involving reproductive cells in both human and animal contexts, including infertility and reproductive toxicology. Hamilton Thorne's innovative laser technologies significantly reduce the time required to develop transgenic animal models and minimize cell damage during procedures, resulting in higher yields. The company caters to a diverse clientele, including pharmaceutical and biotechnology firms, fertility clinics, and prominent university research centers, with notable customers such as Harvard, MIT, and Pfizer.

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to reduce metabolic risk and prevent chronic diseases. Founded in 2008, Newtopia utilizes a proprietary virtual platform that combines personal genetics with social and psychological insights to create personalized health plans. By addressing unhealthy lifestyles, the company aims to mitigate the economic and social consequences associated with obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to make healthier lifestyle choices, demonstrating a proven model with an 80% success rate among early clients. The company targets partnerships with insurers, self-insured employers, and brands, offering sustainable health outcomes and a significant return on investment, making it a promising B2B collaborator in the health sector.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Medicago Inc. is a biotechnology company based in Quebec City, Canada, specializing in the research, development, production, and commercialization of vaccines. The company employs proprietary plant-based manufacturing and Virus-Like Particle (VLP) technologies to create innovative vaccines and therapeutics aimed at infectious diseases and public health challenges. Medicago's product pipeline includes a candidate for the H5N1 pandemic influenza VLP vaccine, which has successfully completed a Phase I clinical trial, as well as an H1N1 VLP vaccine and seasonal influenza vaccines. The company has established collaboration agreements with organizations such as Viridis S.A. and Genopole biopark for the manufacturing of its vaccines, and with Philip Morris International to develop a therapeutic protein. Medicago was incorporated in 1997 and continues to focus on addressing emerging health threats through its advanced vaccine technologies.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, focused on developing innovative therapies for cancer treatment. Its primary product, pelareorep, is an immuno-oncology agent derived from reovirus, designed to enhance the immune system's ability to target and eliminate tumors, particularly those with an activated Ras pathway. The company has established collaboration agreements with Merck KGaA and Pfizer to explore the use of pelareorep in combination with other treatments for specific types of cancer, including hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer. In addition to pelareorep, Oncolytics Biotech is advancing other projects in its pipeline aimed at various cancers, including breast and gastrointestinal cancers. Founded in 1998, Oncolytics Biotech continues to seek novel approaches to address unmet medical needs in oncology.

Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration. The company is particularly focused on addressing severe disorders, with a key program centered on creating an oral therapeutic drug for Duchenne muscular dystrophy. This drug is designed to correct the dysregulation identified by Satellos as a fundamental cause of the disease's progressive nature. Through its research and development efforts, Satellos aims to provide effective treatments that enhance muscle regeneration and improve the quality of life for individuals affected by this debilitating condition.